Overweight Clinical Trials in Minneapolis, Minnesota

5 studies are recruiting for overweight in Minneapolis, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Minneapolis, Minnesota

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

2. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

   The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   International Diabetes Center, Minneapolis, Minnesota

   Locations

   74 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07533175 on ClinicalTrials.gov

3. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

   The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

   Stage

   Phase 3

   Ages

   45 to 99

   Site

   Minneapolis Heart Institute Foundation, Minneapolis, Minnesota

   Locations

   783 in total

   Run by

   Amgen

   See if you can join NCT07037433 on ClinicalTrials.gov

4. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

   This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide …

   Stage

   Phase 3

   Ages

   8 to 18

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   121 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07253285 on ClinicalTrials.gov

5. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota

   Locations

   117 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov